Next Article in Journal
Flanker Task Performance in Isolated Dystonia (Blepharospasm): A Focus on Sequential Effects
Previous Article in Journal
Validity and Reliability of a Test Battery to Assess Change of Directions with Ball Dribbling in Para-footballers with Cerebral Palsy
Open AccessReview

Using Light for Therapy of Glioblastoma Multiforme (GBM)

1
School of Physiology Pharmacology and Neuroscience, University of Bristol, Bristol BS8 1TD, UK
2
Institute of Living Systems, Immanuel Kant Baltic Federal University, 236041 Kaliningrad, Russia
3
Faculty of Medicine, King Abdul-Aziz University, Alehtifalat st., Jeddah 21589, Saudi Arabia
4
Children’s Brain Tumour Research Centre, Nottingham Biodiscovery Institute, School of Medicine, University of Nottingham, Nottingham NG7 2RD, UK
*
Author to whom correspondence should be addressed.
Brain Sci. 2020, 10(2), 75; https://doi.org/10.3390/brainsci10020075
Received: 20 December 2019 / Revised: 16 January 2020 / Accepted: 27 January 2020 / Published: 31 January 2020
(This article belongs to the Section Neuroglia)
Glioblastoma multiforme (GBM) is the most malignant form of primary brain tumour with extremely poor prognosis. The current standard of care for newly diagnosed GBM includes maximal surgical resection followed by radiotherapy and adjuvant chemotherapy. The introduction of this protocol has improved overall survival, however recurrence is essentially inevitable. The key reason for that is that the surgical treatment fails to eradicate GBM cells completely, and adjacent parenchyma remains infiltrated by scattered GBM cells which become the source of recurrence. This stimulates interest to any supplementary methods which could help to destroy residual GBM cells and fight the infiltration. Photodynamic therapy (PDT) relies on photo-toxic effects induced by specific molecules (photosensitisers) upon absorption of photons from a light source. Such toxic effects are not specific to a particular molecular fingerprint of GBM, but rather depend on selective accumulation of the photosensitiser inside tumour cells or, perhaps their greater sensitivity to the effects, triggered by light. This gives hope that it might be possible to preferentially damage infiltrating GBM cells within the areas which cannot be surgically removed and further improve the chances of survival if an efficient photosensitiser and hardware for light delivery into the brain tissue are developed. So far, clinical trials with PDT were performed with one specific type of photosensitiser, protoporphyrin IX, which tends to accumulate in the cytoplasm of the GBM cells. In this review we discuss the idea that other types of molecules which build up in mitochondria could be explored as photosensitisers and used for PDT of these aggressive brain tumours. View Full-Text
Keywords: glioblastoma multiforme; photodynamic therapy; photosensitiser glioblastoma multiforme; photodynamic therapy; photosensitiser
Show Figures

Figure 1

MDPI and ACS Style

Vasilev, A.; Sofi, R.; Rahman, R.; Smith, S.J.; Teschemacher, A.G.; Kasparov, S. Using Light for Therapy of Glioblastoma Multiforme (GBM). Brain Sci. 2020, 10, 75.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop